Brand Name: Adcetris®
Brentuximab vedotin (Adcetris®) is a therapy consisting of a CD30-directed antibody attached to a cell-killing drug. CD30 is a protein found on the surface of certain lymphoma cells. When brentuximab vedotin is internalized by the lymphoma cells, the cell-killing drug is released, causing lymphoma cells to die.
Brentuximab vedotin is used for patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and mycosis fungoides (MF) that expresses CD30.
Brentuximab vedotin is given intravenously.
Treatment with brentuximab vedotin can improve symptoms of skin lymphoma and reduce skin lesions. Brentuximab vedotin does not work in all patients. It is important to discuss with your physician whether this might be an appropriate therapy and what the expected results might be for your individual disease.
Brentuximab vedotin can cause peripheral neuropathy (numbness and tingling in the hands and feet).
The following is not an exhaustive list of the possible side effects. For a complete list of possible side effects, please see the manufacturer's available information on the specific therapy and talk to your treating physician.
Common side effects experienced by patients receiving brentuximab vedotin are peripheral neuropathy and certain gastrointestinal side effects like diarrhea and nausea.